Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
About this episode
This episode features a dialogue on the role of perioperative immunotherapy in treating head and neck cancer, focusing on patient-centered discussions and clinical evidence.
Faculty: Adam J. Luginbuhl, MD This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.
More episodes of CME
- No Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
- Closing the Gaps: Global Implementation of Lipid Guidelines
- Translating Evidence Into Action: Nonsteroidal MRAs in Patients With HF
- Unblocking Clinical Inertia: The CMI Era in oHCM Care
- Chairperson’s Perspective: Reframing First-Line and Subsequent Care in Advanced Urothelial Carcinoma – Clinical Implications of the Updated NCCN Guidelines
- Chairperson’s Perspective: HER2 in Solid Tumors – From Pathology to Personalized Treatment Plans
Explore listener stats, chart rankings, contacts and more on the CME podcast page.